Non-Hodgkin's Lymphoma News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

12-year-old Blanchard boy recovering from Lymphoma diagnosis - kfor.com



kfor.com
 
12-year-old Blanchard boy recovering from Lymphoma diagnosis 
kfor.com
"He was eventually diagnosed with a type of cancer called Lymphoma, and specifically a T-Cell lymphoblastic lymphoma," explained Pediatric oncologist Dr. Joel Thompson. It is a very rare subtype of non-Hodgkin's lymphoma that tends to develop in ...

 


Samanta Osorio Negron: Cancer followed death of family's father - Austin American-Statesman



Austin American-Statesman
 
Samanta Osorio Negron: Cancer followed death of family's father 
Austin American-Statesman
Just before Valentine's Day a few weeks later, a still-grieving Samanta Osorio Negron got the news: She had stage 2 non-Hodgkin's lymphoma and needed chemo immediately. She weighed less than 85 pounds when she started treatment, but she was able ...

and more » 


Chula Vista, CA - Star-News



Chula Vista, CA 
Star-News
Castaneda said hearing the diagnosis was difficult but he said he remains positive knowing non-Hodgkin's Lymphoma is one of the few cancers that can be treated and is curable. ?From the very beginning, my doctor was very clear about the fact that ...

and more » 


Nordic Nanovector Capital Markets Day 2017 - Markets Insider



Nordic Nanovector Capital Markets Day 2017 
Markets Insider
Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin's Lymphoma (NHL). NHL is an indication with substantial unmet medical ...

and more » 


ADC Therapeutics Raises $200M to Fund Two Lead Programs in Non-Hodgkin's Lymphoma - Lymphoma News Today



Lymphoma News Today
 
ADC Therapeutics Raises $200M to Fund Two Lead Programs in Non-Hodgkin's Lymphoma 
Lymphoma News Today
Earlier this year, ADC Therapeutics presented the preliminary results from this trial during the 14th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland. Results revealed promising overall response rates and low-degree ...

 


Teen beat cancer, weathered brother's death before making half-court shot at 76ers game - Philly.com



Philly.com
 
Teen beat cancer, weathered brother's death before making half-court shot at 76ers game 
Philly.com
At 14, he was diagnosed with a rare type of non-Hodgkin's lymphoma and in August, he lost his big brother, Andrew, in a car accident. The often random nature of life had hit the Shelly family hard recently, but it was a bit of random luck that got ...

 


Immune Design's G100 Receives EMA's Orphan Drug Designation for Follicular Non-Hodgkin's Lymphoma - Lymphoma News Today



Immune Design's G100 Receives EMA's Orphan Drug Designation for Follicular Non-Hodgkin's Lymphoma 
Lymphoma News Today
The EMA orphan drug designation ? granted for investigational therapies for rare diseases ? gives Immune Design certain benefits, including protocol assistance, reduced fees for regulatory procedures, and market exclusivity within the European Union ...

 


Gazyva OK'd for Previously Untreated Advanced Follicular Lymphoma - Monthly Prescribing Reference



Gazyva OK'd for Previously Untreated Advanced Follicular Lymphoma 
Monthly Prescribing Reference
... chemotherapy (CHOP, CVP or bendamustine) regimen was chosen by each study site prior to study enrollment. Of the total patients with previously untreated non-Hodgkin's lymphoma (NHL), 1,202 had advanced follicular lymphoma (stage II bulky, III or IV).
FDA Approves Genentech's Gazyva for Previously Untreated Advanced Follicular Lymphoma Business Wire (press release)

all 8 news articles » 


Global Non-Hodgkin Lymphoma Therapeutics Market - Growth, Trends & Forecasts to 2022 - Research and Markets - Business Wire (press release)



Global Non-Hodgkin Lymphoma Therapeutics Market - Growth, Trends & Forecasts to 2022 - Research and Markets 
Business Wire (press release)
The National Cancer Institute reports an estimated 72580 new cases and 20150 deaths in 2016, due to non-Hodgkin's lymphoma. Although the market has a strong pipeline, no late-stage drugs in the NHL pipeline are expected to achieve blockbuster status, ...

and more » 


FDA Approves New Treatment for Mantle Cell Lymphoma - Managed Care magazine



Lymphoma News Today
 
FDA Approves New Treatment for Mantle Cell Lymphoma 
Managed Care magazine
According to the National Cancer Institute, it represents 3% to 10% of all non-Hodgkin's lymphoma cases in the U.S. Mantle cell lymphoma is a cancer of the lymph system, a part of the body's immune system made up of lymph tissue, lymph nodes, the ...
FDA Grants Accelerated Approval to Calquence for Mantle Cell Lymphoma Lymphoma News Today
FDA approves new treatment for adults with mantle cell lymphoma FDA.gov
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma - Full Text View ... ClinicalTrials.gov
MPR 
all 85 news articles »